Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

This trial is studying ways to prevent a serious side effect — dangerously low white blood cell counts (neutropenia) — in patients with metastatic triple-negative breast cancer (TNBC) who are receiving the drug sacituzumab govitecan. Neutropenia from this treatment increases infection risk, and the study is testing whether a specific preventive strategy can reduce this risk. **You may be eligible if...** - You are 19 or older - You have been confirmed to have metastatic triple-negative breast cancer (ER-, PR-, HER2-negative) - You are in good general health (ECOG score 0–1) - Your life expectancy is at least 12 weeks - Your disease is measurable or detectable on scans - Your blood counts and organ function meet the required levels **You may NOT be eligible if...** - You have active brain metastases that are not well-controlled - You have serious autoimmune disease or a history of severe immune-related reactions - Your organ function is insufficient for treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.